Search PubMed⌕ Search

Biomedical subjects

H Bricaire

Publications and source records attributed to H Bricaire.

At least 19 recordsLinked to original sources

[How should the plasma ACTH level in treated Addison's disease patients be interpreted?].

The ACTH plasma levels of 73 treated Addisonian patients have been analysed and compared to those obtained in 40 normal subjects after metyrapone-induced nocturnal cortisol deprivation (75 to 700 pg/ml). Using this new criterion, it appears that patients with ACTH plasma levels lower than 75 pg/ml are most often over-treated; those with ACTH plasma levels between 75 to 700 pg/ml are most often well substituted; and those with ACTH plasma levels higher than 700 pg/ml are under-treated. In this latter group coincidental high plasma renin activity is generally present, pointing to the possible role of the renin-angiotensin system in maintaining high ACTH plasma levels.

Addison Disease↗

[Osteoarticular pathology, hypercalcemia and adrenal insufficiency. Analysis of 113 cases of adrenal insufficiency].

Rheumatologic manifestations, ectopic calcification and hypercalcemia of adrenal insufficiency (IS) were evaluated by a prospective study (S1) of 20 patients with IS and a retrospective analysis of 93 cases of IS (S2). When routine investigations were conducted they revealed very frequent osteoarticular lesions (19 of 20 cases, S1). Painful manifestations (arthralgia, myalgia), variable with fluctuations in the IS affection were observed in both groups (S1, S2). Analysis of group S1 showed a high number of periarthritic attacks (9 of 20 cases), and a significantly higher incidence of tendinous calcifications (p less than 0.03) and of multiple tendinous calcification disease (MCTM) (p less than 0.05) in relation to 20 matched controls. This combined affection MCTM-IS has not been reported previously. Calcification could be due to glucocorticoid deficiency, the only common factor for all cases, and the frequent calcification of ear pinna (greater than 30% of cases in the 2 groups) could be related to the same deficiency. Finally, reported in the 81 case-reports were 18 episodes of hypercalcemia, emphasizing the unrecognized frequency of this disturbance whose determining role is unclear.

Adrenal Insufficiency↗

[Rapid beta 1-24-corticotropin test in the exploration of the corticotropic axis. 71 cases].

The reliability of the beta 1-24 corticotropin test, which is both cheap and safe, in the assessment of the hypothalamic-pituitary-adrenocortical function was re-evaluated by comparing its results with those of the metyrapone test in 71 subjects: 30 controls and 51 patients with suspected pituitary-adrenal dysfunction. Response to a 500 micrograms intramuscular injection of beta 1-24 corticotropin was evaluated by measuring the 60 min plasma cortisol levels; 4.5 g of metyrapone divided into 6 doses were then administered orally and response was evaluated by measuring plasma 11-desoxycortisol levels. A highly significant correlation (r = 0.79; p less than 0.001) was observed between plasma cortisol and plasma 11-desoxycortisol levels. The results were best interpreted by expressing the values obtained as plasma cortisol concentrations which, in normal subjects are at least 21 micrograms/100 ml. The rapid beta 1-24 corticotropin test was found to be very reliable (sensitivity 90%, specificity 100%) to detect adrenal insufficiency, irrespective of the organs affected on the hypothalamic-adrenocortical axis.

Adolescent↗

[Hematologic repercussions of disorders of thyroid secretion].

The effects on blood of abnormal thyroid hormone secretion were investigated in a prospective study involving 80 patients. Anaemia, when present, could usually be ascribed to association with another pathology. In non-anaemic patients an excess or a deficiency of thyroid hormones had opposite effects on erythrocytes. Leucocytes as a whole were not influenced by hypothyroidism, but untreated hyperthyroidism seemed to be responsible for a relative decrease in the number of neutrophils and a relative increase in the number of eosinophils and mononucleate cells. Platelet counts were unaffected by variations in thyroid hormone levels. Excluding the effects on blood of synthetic antithyroid drugs, the changes observed were generally reversible after correction of the abnormal hormone secretion.

Adult↗

[Adrenal adenoma secreting exclusively estrogens in a woman during her reproductive period. 11-year follow-up].

Feminizing tumours are rare, most are malignant, and they are usually seen in children and male adults. We report an 11-year follow-up of a feminizing adrenal tumour which was unusual on three accounts: it was a benign adenoma, it secreted estrogens only and the patient was an female in her active reproductive years. To our knowledge, similar cases have not yet been published.

Adenoma↗

Effects of 10 days administration of percutaneous dihydrotestosterone on the pituitary-testicular axis in normal men.

Dihydrotestosterone (DHT) was administered percutaneously in a dose of 125 mg twice daily for 10 days to 12 normal men. Basal plasma levels of testosterone (T), 17 beta-estradiol (E2), and LH were measured every 2 days in these men and every 5 days in subjects from a control group receiving placebo. The daytime course of plasma hormone levels between two DHT applications was studied in six men. LRH tests were performed in nine men before and on day 10 of DHT administration. Plasma levels of free T and free E2, and T - E-binding globulin capacity and affinity were measured in six men before and on days 5 and 10 of DHT administration. Before DHT administration, there was no difference in basal plasma levels of T, DHT, E2, and LH between the control and the DHT-treated group. In the latter group, plasma DHT levels increased sharply from 0.52 +/- (+/- SE) to 3.70 +/- 0.92 ng/ml on day 2 (P less than 0.001) during DHT treatment. Plasma T, E2, and LH levels decreased significantly from 7.33 +/- 0.74 to 1.33 +/- 0.54 ng/ml (P less than 0.001), from 46 +/- 5 to 20 +/- 3 pg/ml (P less than 0.01), and from 7.8 +/- 1 to 4.2 mIU/ml (P less than 0.05), respectively. Except for a small decrease in plasma DHT (P less than 0.05) 12 h after the previous DHT application, hormone levels were stable during the time between the two DHT treatments. The responses of LH and FSH to LRH were not different before and on day 10 of DHT administration. Plasma levels of free T and free E2 as well as those of total T and E2 decreased; however, the percentages of unbound T and E2 were not different before and during DHT administration. T - E-binding globulin capacity and affinity were not modified by DHT administration. Changes in plasma DHT levels were negatively correlated with those in The results of this study demonstrate that 10-days DHT administration has an inhibitory effect on the hypothalamo-pituitary-testicular axis in normal men.

Adult↗

Evaluation of treated acromegalic patients with normal growth hormone levels during oral glucose load.

Twenty-one treated acromegalics with plasma GH levels less than or equal to 5 ng/ml were evaluated during an oral glucose tolerance test (OGTT). Serum insulin-like growth factor (IGF) levels, measured by a competitive binding assay, were high in 10, normal in 8 and low in 3 patients. Urinary calcium excretion (Ca U), measured over 24 h, was elevated in 9 of the 10 patients whose IGF levels were high, whereas only 1 of the patients with normal or low IGF levels was hypercalciuric. A paradoxical rise in GH following TRH injection was observed in 5 of the 10 patients whose IGF levels were high, whereas all patients with normal or low IGF levels showed no GH response to TRH. GH levels greater than or equal to 10 ng/ml occurred during ornithine (ORN) administration in 6 of the 18 patients with normal or high IGF levels. The remaining 12 patients with no GH rise during ORN included 2 cases in which IGF levels were high and GH rose following TRH, and 2 cases in which IGF levels were normal and GH levels were greater than or equal to 10 ng/ml during insulin-induced hypoglycaemia (IIH), thus excluding a GH deficiency. These results show that acromegaly is not cured in certain treated patients with normal GH levels during OGTT. It seems that IGF and Ca U determinations are valuable indices of activity, in contrast to GH response to ORN. The GH response to TRH is also relatively useful.

Acromegaly↗

[Adrenomyeloneuropathy. Endocrine, clinical and biological study of 4 cases].

Adrenoleukomyeloneuropathy (ALMN) is a rare neurological and endocrine disorder. It usually affects children, and consists of cortical disease and adrenal insufficiency (adrenoleukodystrophy: ALD). An adult form has recently been identified in which medullary disease is associated with an endocrine disorder (adrenomyeloneuropathy AMN). The authors describe the clinical, biological and physiopathological features of four cases of AMN.

Adrenal Insufficiency↗

[Osteoarticular manifestations in adrenal insufficiency].

We conducted a prospective study of the rheumatological manifestations in 20 patients with adrenal failure: 15 women and 5 men with a mean age of 56. Osteo-articular pathology was observed in 19 of the 20 cases (95%). The painful manifestations presented as arthralgia, myalgia or episodes of peri-arthritis; they were associated with active phases of the endocrine disease in 9 cases (45%). The radiological features of these patients were compared with those of age and sex matched controls who were hospitalized for other rheumatological conditions. 11 patients had radiologically visible tendinous calcifications (TC); 6 patients had 3 or more TC. The 20 patients had a total of 31 TC, which was significantly different from the controls. A related finding was calcification of the cartilages of the ears in 4 out of 10 patients (40%). Hypercalcaemia was detected in 5 cases (25%), accompanying episodes of decompensation of the adrenal failure. The pathogenesis of the tendinous calcifications is not clear. Mineralocorticoid treatment can not be considered to be a major aetiological factor for CT, calcification of the ears nor the pain, as its use was very constant. Thus, tendinous calcifications, which have rarely been reported to date, could explain a large part of the painful manifestations of adrenal failure.

Adrenal Insufficiency↗

[Treatments with synthetic antithyroid drugs during pregnancy. Evaluation of the neonatal thyroid function. 25 cases].

Twenty-four hyperthyroid women were treated with antithyroid drugs during 25 pregnancies. The thyroid function of the 21 children who lived was evaluated by standard clinical and laboratory methods. In 8 of these, T3, T4 and TSH were assayed between birth and the 5th day, with timed samplings during the first hours of life. There was no hypothyroxinaemia at birth, but the T4 peak was delayed; T3 was normal. The TSH peak was abnormal in 3 children, one of whom presented with clinical hypothyroidism. All abnormal findings disappeared spontaneously during the first few days of life, except for one child with congenital Grave's disease who had to be treated. On a 6 months to 6 years follow-up all children had normal growth and psychomotor development.

Antithyroid Agents↗

[Gynecomastia: effect of prolonged treatment with dihydrotestosterone by the percutaneous route].

Gynaecomastia is a frequent disorder, sometimes painful or psychologically disturbing. Percutaneous dihydrotestosterone (DHT) was used to treat 30 patients with idiopathic gynaecomastia (IG) and 17 patients in whom the condition was associated with hypogonadism. All patients complaining of pain were relieved. Breast enlargement regressed or was substantially reduced in 22 of the IG patients and in all cases with hypogonadism, except those with gonadal dysgenesis. Plasma levels of testosterone and 17 beta-estradiol were significantly lowered in patients with IG as compared with controls. There was a significant increase in plasma DHT levels and in plasma androgen/estradiol ratio in all cases. The beneficial effects of the drug were manifest within 1 to 2 months in responsive patients. These effects may be due to a local and/or systemic activity. It is suggested that this medium-term treatment without side-effects should be tried in all cases of hypogonadism with gynaecomastia and in IG before considering more drastic therapeutic measures.

Administration, Topical↗

Studies on the treatment of idiopathic gynaecomastia with percutaneous dihydrotestosterone.

We have studied clinical and endocrine parameters in a group (group A) of forth men referred to us because of persistent idiopathic gynaecomastia (of more than 18 months duration), before and during the administration of percutaneous dihydrotestosterone (DHT). The endocrine parameters (testosterone (T), 17 beta-oestradiol (E2), DHT, gonadotrophins (FSH and LH) and prolactin (PRL), were compared to those of control groups of 12 healthy men on DHT therapy (group B) and 10 on placebo (group C). Local administration of DHT was followed by the complete disappearance of gynaecomastia in 10 patients, partial regression in 19 and no change in 11 patients after 4 to 20 weeks of percutaneous DHT (125 mg twice daily). Before treatment the T + DHT/E2 ratio was significantly (P less than 0.001) lower in group A 244 +/- 21 (SEM) than in groups B and C (361 +/- 21) while T, DHT and E2 concentrations were all within the normal range. During DHT treatment plasma hormone levels were measured in 26 patients from group A: DHT levels increases significantly (day 0: 1.63 +/- 0.14 nmol/l; day 15: 12.8 +/- 1.6 nmol/l, P less than 0.001) while T and E2 levels fell significantly (T: day 0: 22.6 +/- 1.2 nmol/l; day 15: 11.0 +/- 1.5 nmol/l, P less than 0.001; E2: day 0: 110.5 +/- 7.12 pmol/l; day 15: 86.79 +/- 9.4 pmol/l, P less than 0.01). The T/E2 ratio decreased from 231 +/- 20 to 164 +/- 27 (P less than 0.05) while the T + DHT/E2 ratio increased significantly (P less than 0.02) to a normal mean value (day 15: 354 +/- 57).(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗

Peptides related to the NH2-terminal end of proopiocortin in man.

Peptides related to the NH2-terminus of proopiocortin in man were studied with three different RIAs directed toward gamma 3MSH, human 16K, and mouse 16K. The culture medium derived from a human corticotropic adenoma (SCH medium), which had previously been used as a human reference standard, generated competitive binding curves parallel to that of purified human 16K in all three RIA systems. Gel exclusion chromatography performed with pituitary-derived materials (adenoma extract and medium, and plasma from patients with Nelson's syndrome) showed that the overall immunoreactive gamma 3MSH eluted as one major peak at the position of human 16K. Its molecular weight estimated under denaturing conditions was 11,000. Gel exclusion chromatography performed with nonpituitary-derived materials (tumor extract and plasma from patient with the ectopic ACTH syndrome) showed that a major peak eluted at the position of human 16K, and a smaller molecular weight peptide eluted in a position intermediary between that of human 16K and synthetic gamma 3MSH. These data show that immunoreactive gamma 3MSH is indeed identical to human 16K in pituitary-derived materials. A different processing of the proopiocortin molecule is likely to occur in nonpituitary tumors and will result in the release of a smaller molecular weight peptide. The exact nature of this peptide is not known. It is speculated that it may serve as a nonpituitary tumor marker.

Adenoma↗